Cerebrospinal Fluid Leak
Conditions
Brief summary
The objective of the study is to clinically assess the safety and effectiveness of LIQOSEAL® as a means of reducing intra- as well as post-operative CSF leakage in patients undergoing elective cranial intradural surgery with a dural closure procedure to show noninferiority compared to a control group.
Interventions
DEVICELIQOSEAL
Adjunctive bioresorbable patch
DEVICEDuraSeal, Adherus
synthetic absorbable sealants
Sponsors
Polyganics BV
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
pre-operative 1. Subjects who are able to provide written informed consent prior to participating in the clinical investigation. 2. Subjects who are ≥ 18 years old. 3. Subjects who are able to comply with the follow-up or other study requirements. 4. Subjects wo are planned for elective surgery including a trepanation to reach the subdural infratentorial space (with lower limit of incision defined as the lower edge of C2) in whom a dural incision will be closed. 5. Female subjects of child bearing potential must agree to use a form of contraception from the time of signing the informed consent form through 90 days post-surgery. intra-operative 1. Subjects with surgical wound classification Class I/Clean. 2. Subjects with minimally 5 mm of dural space surrounding dural opening.
Exclusion criteria
pre-operative 1. Female subjects who are pregnant or breastfeeding. 2. Subjects with an assumed impaired coagulation due to medication or otherwise. 3. Subjects suspected of an infection requiring antibiotics. 4. Subjects with any type of dural diseases in planned dural closure area. 5. Subjects requiring re-opening of planned surgical area within 90 days after surgery. 6. Subjects with a known allergy to any of the components (Lactide-Caprolactone co-polyester; Butanediol-BDI co-polyurethane; Polyethylene glycol Succinimidyl Gluterate; Disodium hydrogen phosphate or D&C Green No 6) of LIQOSEAL®. 7. Subjects who previously received a LIQOSEAL®. 8. Subjects who previously participated in this study or any investigational drug or device study within 30 days of screening. 9. Subjects with a presence of hydrocephalus. 10. Subjects with contra-indication to MRI \[cardiac pacemaker or defibrillator, severe claustrophobia, injured by a metallic object that was not removed, cochlear (ear) implants, metallic implants \[e.g. knee replacement\]. intra-operative 1. Subjects in whom elevation of PEEP has a potential detrimental effect. 2. Subjects who will require a CSF drain, electrodes or other devices passing the dural layer or extra to intracranial bypass surgery. 3. Subjects who have primary closure of the dura mater with synthetic, nonautologous or autologous material other than galea. 4. Subjects in whom no intra-operative CSF leakage is present after primary closure of the dura mater with elevation of PEEP. 5. Subjects who after primary closure (including galea, if applicable) of the dura mater have a gap \> 3 mm. 6. Subjects whom dural opening size including 5 mm margin exceeds patch size (8 x 8 cm).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite endpoint defined as successful dural repair without any of the following compared to the control group: intra-operative CSF leakage percutaneous CSF leak significant pseudomeningocele wound infection | 30 days |
Countries
Austria, Belgium, Germany, Italy, Netherlands, Switzerland, United States
Outcome results
None listed